{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-088455","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2026-07-30T11:05:32+00:00","discovered_at":"2026-07-30T11:10:00.288625+00:00","generated_at":"2026-07-30T11:10:33.126322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bicycle Therapeutics Q2 net loss $50.3M ($0.72/share); cash $510.1M; clinical progress on nuzefatide and zelenectide","bullets":["Net loss of $50.3M ($0.72 per share) for Q2 2026, compared to $79.0M ($1.14) in Q2 2025.","Cash and equivalents of $510.1M as of June 30, 2026; expected cash runway into 2030.","R&D expenses fell to $41.2M from $71.0M, driven by workforce reduction and lower zelenectide costs.","First patient dosed in Phase 2 trial of nuzefatide in recurrent pancreatic cancer in April 2026.","Expanded Clinical Advisory Board with Thomas Powles, MD, a leader in urothelial cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-088455","json":"https://secwatch.observer/filing/0001104659-26-088455.json","markdown":"https://secwatch.observer/filing/0001104659-26-088455.md","text":"https://secwatch.observer/filing/0001104659-26-088455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/0001104659-26-088455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/tm2621593d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:10:33.126322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}